New drug targets rare leukemia mutation in early trial
NCT ID NCT03974217
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-phase study tests whether the drug talazoparib can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a specific mutation in the cohesin complex. The trial includes 13 participants who cannot receive standard intensive chemotherapy. The main goal is to see if the drug reduces leukemia cells in the bone marrow by at least half.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.